secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rafael Holdings, Inc. (RFL)
CIK:        0001713863
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0001213900-26-046380
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rafael Holdings subsidiary Cyclo Therapeutics licenses MIT patent for cyclodextrins in ApoE4+ Alzheimer's
--------------------------------------------------------------------------------

- Exclusive license covers U.S. Patent No. 12285440 for cyclodextrins in ApoE4-positive Alzheimer's patients.
- ApoE4 variant present in 50-70% of Alzheimer's patients; Trappsol Cyclo targets cholesterol transport in CNS.
- Phase 3 results for Transport NPC program due in calendar Q3 2026, per COO Joshua Fine.
- CEO Howard Jonas calls the license a transformative milestone for the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1713863/000121390026046380/0001213900-26-046380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1713863/000121390026046380/ea0287258-8k_rafael.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-046380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer